首頁 > 市場調查報告書 > 製藥

藥物開發臨床實驗臨床開發

市場調查報告書

商品編碼

1536008

臨床試驗市場- 依階段（I、II、III、IV）、研究設計（介入、觀察、擴大訪問）、服務類型（外包、內部）、治療領域（腫瘤學、皮膚病學、神經病學、心臟病學） - 全球預測（2024 - 2032）

Clinical Trials Market - By Phase (I, II, III, IV), Study Design (Interventional, Observational, Expanded Access), Service Type (Outsourcing, In-house), Therapeutic Area (Oncology, Dermatology, Neurology, Cardiology) - Global Forecast (2024 - 2032)

出版日期: 2024年06月20日 | 出版商:

Global Market Insights Inc. | 英文 140 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

在領先研究公司案例研究增加的推動下，全球臨床試驗市場 2024 年至 2032 年間複合年成長率將達到 5.4%。這些研究為新療法的有效性和安全性提供了寶貴的見解，推動了廣泛和多樣化的臨床試驗的需求。研究公司正在投資先進的方法和技術來進行這些試驗，解決各種醫療狀況和患者群體的問題。例如，2024 年8 月，NeuroSense Therapeutics Ltd. 是一家處於後期臨床開發階段的生物技術公司，專注於嚴重神經退化性疾病的新療法，宣布其IIb 期研究(PARADIGM) 的12 個月鐵生物標記物結果呈陽性。

隨著案例研究證明了新療法和創新治療方法的益處，人們更加關注進行嚴格的臨床試驗來驗證這些發現。慢性病盛行率的上升和對個人化醫療的持續追求進一步支持了這一趨勢。持續不斷的案例研究不僅支持新療法的開發，還增強了法規核准和市場准入，推動臨床試驗領域的需求並推動整體醫療保健格局的發展。

整個臨床試驗產業根據階段、研究設計、服務類型、治療領域和地區進行分類。

從階段來看，III期臨床試驗市場收入從2024年到2032年將實現令人稱讚的複合年成長率。的全面資料。這一階段對於獲得市場批准並確保治療符合嚴格的監管標準至關重要。慢性病的盛行率不斷上升以及對創新療法的需求推動了對 III 期試驗的需求，使其成為藥物開發過程中的焦點。

在研究設計方面，觀察性研究部分將從 2024 年到 2032 年出現顯著資料。的表現。這些研究對於評估治療的長期效果、病患依從性和比較效果很有價值。對個人化醫療和實證實踐的日益關注推動了對觀察研究的需求。此外，監管機構和醫療保健提供者利用這些研究來提供指導方針並改善患者護理，進一步增加了對全面觀察資料的需求。

2024年至2032年，歐洲臨床試驗市場將呈現顯著的複合年成長率。慢性病盛行率的上升和創新療法的推動推動了對臨床試驗的需求。此外，歐洲對臨床研究和病患安全高標準的重視增強了該地區進行試驗的吸引力。這些因素加上支持性的監管框架，推動了歐洲臨床試驗領域的顯著成長。

產業生態系統分析
產業影響力
- 成長動力
  - 全球慢性病盛行率不斷上升
  - 將臨床試驗外包給 CRO 的需求不斷成長
  - 政府和非政府對臨床試驗的資助增加
  - 在亞太國家進行臨床試驗的機會不斷增加
- 產業陷阱與挑戰
  - 臨床研究缺乏熟練的勞動力
  - 發展中國家的基礎建設障礙
  - 北美和歐洲進行臨床試驗所面臨的挑戰
成長潛力分析
臨床試驗量分析
- 2021-2023 年臨床試驗量分析（按地區）
- 2021-2023 年臨床試驗量分析（依開發階段）
- 2021-2023 年臨床試驗量分析（依適應症）
監管環境
- 美國
- 歐洲
- 亞太地區
  - 新加坡
  - 馬來西亞
  - 印尼
  - 泰國
  - 韓國
  - 菲律賓
臨床試驗—亞太區優勢
波特的分析
PESTEL分析

第 4 章：競爭格局

介紹
公司矩陣分析
併購格局
主要市場參與者的競爭分析
競爭定位矩陣
戰略儀表板

第 5 章：市場估計與預測：按階段，2021 - 2032

主要趨勢
第一階段
第二階段
第三階段
第四階段

第 6 章：市場估計與預測：根據研究設計，2021 - 2032

主要趨勢
介入研究
觀察性研究
擴大訪問研究

第 7 章：市場估計與預測：按服務類型，2021 - 2032 年

主要趨勢
外包服務
內部服務

第 8 章：市場估計與預測：按治療領域，2021 - 2032 年

主要趨勢
自體免疫疾病
腫瘤學
心臟病學
傳染病
皮膚科
眼科
神經病學
血液學
其他治療領域

第 9 章：市場估計與預測：按地區，2021 - 2032

主要趨勢
北美洲
- 美國
- 加拿大
歐洲
- 德國
- 英國
- 法國
- 西班牙
- 義大利
- 波蘭
- 荷蘭
- 瑞士
- 歐洲其他地區
亞太地區
- 中國
- 日本
- 印度
- 澳洲
- 韓國
- 新加坡
- 馬來西亞
- 印尼
- 泰國
- 菲律賓
- 亞太地區其他地區
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 拉丁美洲其他地區
中東和非洲
- 沙烏地阿拉伯
- 南非
- 阿拉伯聯合大公國
- 中東和非洲其他地區

第 10 章：公司簡介

Charles River Laboratories (MPI Research)
Clinipace Inc.
Eli Lilly and Company
ICON plc
IQVIA Inc
Laboratory Corporation of America Holdings (Covance Inc)
Medpace, Inc.
Merck & Co
Parexel International Corporation
Pfizer Inc.
SGS SA
Syneos Health
The Emmes Company, LLC
Thermo Fisher Scientific (PPD Inc)
Veeda Clinical Research
Worldwide Clinical Trials
WuXi AppTech

簡介目錄

Product Code: 5029

Global Clinical Trials Market will witness 5.4% CAGR between 2024 and 2032 fueled by an increase in case studies from leading research companies. These studies provide valuable insights into the efficacy and safety of new treatments, driving the need for extensive and diverse clinical trials. Research companies are investing in advanced methodologies and technologies to conduct these trials, addressing various medical conditions and patient populations. For instance, in August 2024, NeuroSense Therapeutics Ltd., a biotechnology firm in late-stage clinical development focused on novel treatments for severe neurodegenerative diseases, announced positive 12-month iron biomarker results from its Phase IIb study (PARADIGM).

As case studies demonstrate the benefits of novel therapies and innovative treatment approaches, there is a heightened focus on conducting rigorous clinical trials to validate these findings. This trend is further supported by the rising prevalence of chronic diseases and the ongoing quest for personalized medicine. The continuous flow of case studies not only supports the development of new treatments but also enhances regulatory approvals and market entry, propelling demand within the clinical trials sector and advancing the overall healthcare landscape.

The overall Clinical Trials Industry is classified based on the phase, study design, service type, therapeutic area, and region.

Based on phase, the clinical trials market revenue from the phase III segment will register a commendable CAGR from 2024 to 2032. Phase III trials involve large patient populations and are designed to confirm the results of earlier phases, providing comprehensive data on a drug's efficacy and potential side effects. This stage is crucial for gaining market approval and ensuring that treatments meet stringent regulatory standards. The increasing prevalence of chronic diseases and the need for innovative therapies drive demand for Phase III trials, making them a focal point in the drug development process.

In terms of study design, the observational study segment will witness an appreciable growth from 2024 to 2032. Unlike interventional trials, observational studies collect data without influencing treatment decisions, providing insights into how therapies perform in everyday clinical settings. These studies are valuable for assessing long-term effects, patient adherence, and comparative effectiveness of treatments. The increasing focus on personalized medicine and evidence-based practice drives the demand for observational research. Additionally, regulatory agencies and healthcare providers use these studies to inform guidelines and improve patient care, further boosting the need for comprehensive observational data.

Europe clinical trials market will exhibit a notable CAGR from 2024 to 2032. European countries offer a diverse patient population and regulatory environment conducive to clinical trials, making them attractive for global studies. The rising prevalence of chronic diseases and the push for innovative therapies drive the demand for clinical trials. Additionally, Europe's emphasis on high standards for clinical research and patient safety enhances the attractiveness of the region for conducting trials. The combination of these factors, along with supportive regulatory frameworks, fuels significant growth in the European clinical trials sector.

Chapter 1 Methodology & Scope

1.1 Market scope & definitions
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates & calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360° synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Increasing prevalence of chronic diseases across the globe
  - 3.2.1.2 Growing demand for outsourcing clinical trials to CROs
  - 3.2.1.3 Rise in government and non-government funding for clinical trials
  - 3.2.1.4 Growing opportunities for conducting clinical trials in countries of Asia Pacific
- 3.2.2 Industry pitfalls & challenges
  - 3.2.2.1 Lack of skilled workforce in clinical research
  - 3.2.2.2 Infrastructural barriers in developing countries
  - 3.2.2.3 Challenges faced in North America & Europe for conducting clinical trials
3.3 Growth potential analysis
3.4 Clinical trials volume analysis
- 3.4.1 Clinical trials volume analysis, by region, 2021-2023
- 3.4.2 Clinical trials volume analysis, by phase of development, 2021-2023
- 3.4.3 Clinical trials volume analysis, by indication, 2021-2023
3.5 Regulatory landscape
- 3.5.1 U.S.
- 3.5.2 Europe
- 3.5.3 Asia Pacific
  - 3.5.3.1 Singapore
  - 3.5.3.2 Malaysia
  - 3.5.3.3 Indonesia
  - 3.5.3.4 Thailand
  - 3.5.3.5 South Korea
  - 3.5.3.6 Philippines
3.6 Clinical trails - Asia Pacific advantage
3.7 Porter's analysis
3.8 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company matrix analysis
4.3 Merger & acquisition landscape
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Phase, 2021 - 2032 ($ Mn)

5.1 Key trends
5.2 Phase I
5.3 Phase II
5.4 Phase III
5.5 Phase IV

Chapter 6 Market Estimates and Forecast, By Study Design, 2021 - 2032 ($ Mn)

6.1 Key trends
6.2 Interventional study
6.3 Observational study
6.4 Expanded access study

Chapter 7 Market Estimates and Forecast, By Service Type, 2021 - 2032 ($ Mn)

7.1 Key trends
7.2 Outsourcing service
7.3 In-house service

Chapter 8 Market Estimates and Forecast, By Therapeutic Area, 2021 - 2032 ($ Mn)

8.1 Key trends
8.2 Autoimmune disease
8.3 Oncology
8.4 Cardiology
8.5 Infectious disease
8.6 Dermatology
8.7 Ophthalmology
8.8 Neurology
8.9 Hematology
8.10 Other therapeutic areas

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

9.1 Key trends
9.2 North America
- 9.2.1 U.S.
- 9.2.2 Canada
9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 France
- 9.3.4 Spain
- 9.3.5 Italy
- 9.3.6 Poland
- 9.3.7 Netherlands
- 9.3.8 Switzerland
- 9.3.9 Rest of Europe
9.4 Asia Pacific
- 9.4.1 China
- 9.4.2 Japan
- 9.4.3 India
- 9.4.4 Australia
- 9.4.5 South Korea
- 9.4.6 Singapore
- 9.4.7 Malaysia
- 9.4.8 Indonesia
- 9.4.9 Thailand
- 9.4.10 Philippines
- 9.4.11 Rest of Asia Pacific
9.5 Latin America
- 9.5.1 Brazil
- 9.5.2 Mexico
- 9.5.3 Argentina
- 9.5.4 Rest of Latin America
9.6 Middle East and Africa
- 9.6.1 Saudi Arabia
- 9.6.2 South Africa
- 9.6.3 UAE
- 9.6.4 Rest of Middle East and Africa